TY - JOUR
T1 - Review of hepatitis B therapeutics
AU - Bhattacharya, Debika
AU - Thio, Chloe L.
N1 - Funding Information:
Financial support. National Institutes of Health (grants AI071820 and AI060449 to C.L.T. and grant KAI066983A to D.B.); UCLA Center for AIDS Research; Johns Hopkins University Center for AIDS Research. Potential conflicts of interest. D.B. and C.L.T.: no conflicts.
PY - 2010/11/15
Y1 - 2010/11/15
N2 - Currently, there are 7 approved therapies for chronic hepatitis B virus (HBV) infection, an increase from just 3 agents 5 years ago. This review will focus on the pharmacology, potency, and adverse events associated with immunomodulatory agents and nucleos(t)ide analogues, with an emphasis on targets of therapy within the HBV life cycle. We will also offer guidelines for the use of available anti-HBV agents and review the emerging challenges in hepatitis B management, including HBV drug resistance, its management, and the potential role of combination therapy.
AB - Currently, there are 7 approved therapies for chronic hepatitis B virus (HBV) infection, an increase from just 3 agents 5 years ago. This review will focus on the pharmacology, potency, and adverse events associated with immunomodulatory agents and nucleos(t)ide analogues, with an emphasis on targets of therapy within the HBV life cycle. We will also offer guidelines for the use of available anti-HBV agents and review the emerging challenges in hepatitis B management, including HBV drug resistance, its management, and the potential role of combination therapy.
UR - http://www.scopus.com/inward/record.url?scp=78349236621&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78349236621&partnerID=8YFLogxK
U2 - 10.1086/656624
DO - 10.1086/656624
M3 - Review article
C2 - 20954965
AN - SCOPUS:78349236621
SN - 1058-4838
VL - 51
SP - 1201
EP - 1208
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 10
ER -